Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Common Equity: 2017-2025

Historic Common Equity for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $926.2 million.

  • Denali Therapeutics' Common Equity fell 29.75% to $926.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $926.2 million, marking a year-over-year decrease of 29.75%. This contributed to the annual value of $1.2 billion for FY2024, which is 19.28% up from last year.
  • Latest data reveals that Denali Therapeutics reported Common Equity of $926.2 million as of Q3 2025, which was down 9.82% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Common Equity peaked at $1.5 billion during Q1 2024, and registered a low of $811.3 million during Q3 2022.
  • For the 3-year period, Denali Therapeutics' Common Equity averaged around $1.2 billion, with its median value being $1.1 billion (2025).
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 113.62% in 2021, then dropped by 29.75% in 2025.
  • Denali Therapeutics' Common Equity (Quarterly) stood at $962.3 million in 2021, then grew by 8.33% to $1.0 billion in 2022, then fell by 1.10% to $1.0 billion in 2023, then increased by 19.28% to $1.2 billion in 2024, then declined by 29.75% to $926.2 million in 2025.
  • Its Common Equity stands at $926.2 million for Q3 2025, versus $1.0 billion for Q2 2025 and $1.1 billion for Q1 2025.